These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12473846)

  • 1. Antiapoptotic activity by HIV protease inhibitors either alone or boostered.
    Matarrese P; Giammarioli AM; Cauda R; Malorni W
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):545-6. PubMed ID: 12473846
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy in the management of HIV infection.
    Vella S; Franca Pirillo M
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl C():23-6. PubMed ID: 9003571
    [No Abstract]   [Full Text] [Related]  

  • 4. [Position of darunavir in antiretroviral therapy].
    Clotet B
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
    [No Abstract]   [Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
    Sloand EM; Kumar PN; Kim S; Chaudhuri A; Weichold FF; Young NS
    Blood; 1999 Aug; 94(3):1021-7. PubMed ID: 10419894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of apoptosis by HIV protease inhibitors.
    Phenix BN; Cooper C; Owen C; Badley AD
    Apoptosis; 2002 Aug; 7(4):295-312. PubMed ID: 12101389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the viral reservoir of latently infected CD4(+) T cells be eradicated with antiretroviral HIV drugs?
    Smith RJ; Aggarwala BD
    J Math Biol; 2009 Nov; 59(5):697-715. PubMed ID: 19165438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific considerations for pharmacoenhancers in antiretroviral therapy.
    Arya V; Robertson SM; Struble KA; Murray JS
    J Clin Pharmacol; 2012 Aug; 52(8):1128-33. PubMed ID: 21712496
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV effects of Viracept persist during long periods of combination therapy.
    Oncology (Williston Park); 1997 Jun; 11(6):915. PubMed ID: 9189946
    [No Abstract]   [Full Text] [Related]  

  • 10. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 11. CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
    Wood E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):347-8. PubMed ID: 14600584
    [No Abstract]   [Full Text] [Related]  

  • 12. Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients.
    Núñez M; Soriano V; López M; Ballesteros C; Cascajero A; González-Lahoz J; Benito JM
    Clin Infect Dis; 2006 Nov; 43(9):1209-12. PubMed ID: 17029144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens.
    Smith KY; Steffens CM; Truckenbrod A; Landay A; Al-Harthi L
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):544-5. PubMed ID: 11981373
    [No Abstract]   [Full Text] [Related]  

  • 14. CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy.
    Meroni L; Varchetta S; Manganaro D; Moscatelli G; Moroni M; Galli M
    AIDS; 1999 Apr; 13(5):621-2. PubMed ID: 10203388
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
    Roger PM; Breittmayer JP; Arlotto C; Pugliese P; Pradier C; Bernard-Pomier G; Dellamonica P; Bernard A
    Clin Exp Immunol; 1999 Dec; 118(3):412-6. PubMed ID: 10594560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 18. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
    Delaugerre C
    Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
    [No Abstract]   [Full Text] [Related]  

  • 19. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
    Duval X
    Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV infection.
    Talbot M
    Clin Evid; 2006 Jun; (15):937-54. PubMed ID: 16973039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.